Review Article
Prognostic Significance of Pretreatment Apolipoprotein A-I as a Noninvasive Biomarker in Cancer Survivors: A Meta-Analysis
Table 1
Main characteristics of all included studies.
| | Study | Year | Cancer type | Country | Included time | Total sample | Follow-up | Cutoff value | Cutoff selection | Treatment methods | Stage | Survival type | NOS |
| | Chen S | 2018 | NSCLC | China | 2008–2010 | 141 | ≥5 years | 1.17 g/l | X-tile software | Mixed | Mixed | OS | 6 | | Shang Z | 2018 | Bladder cancer | China | 2004–2011 | 470 | ≥5 years | 1.19 g/l | ROC analysis | With surgery | No metastasis | OS, CSS | 7 | | Ma M | 2018 | GC | China | 2005–2010 | 1201 | ≥5 years | 1.4 g/l | X-tile software | With surgery | Mixed | OS | 8 | | Chang H | 2018 | NPC | China | 2010–2011 | 1927 | ≥5 years | 1.125 g/l | ROC analysis | No surgery | No metastasis | OS, DFS, LRFS, DMFS | 8 | | Li X | 2017 | BC | China | 2008–2011 | 1044 | ≥5 years | 1.56 g/l | ROC analysis | With surgery | No metastasis | OS, DFS | 7 | | Quan Q | 2017 | CRC | China | 2005–2013 | 721 | ≥5 years | 1.105 g/l | ROC analysis | No surgery | Metastasis | OS | 7 | | Sirnio P | 2017 | CRC | Finland | 2006–2010 | 144 | ≥5 years | 1.235 g/l | ROC analysis | With surgery | Mixed | OS | 6 | | Ma XL-1 | 2016 | HCC | China | 2012–2015 | 224 | <5 years | 1.04 g/l | X-tile software | With surgery | Mixed | OS, TTR | 7 | | Ma XL-2 | 2016 | HCC | China | 2012-2013 | 219 | <5 years | 1.04 g/l | X-tile software | With surgery | Mixed | OS, TTR | 6 | | Quan Q | 2016 | ENKTL | China | 2002–2014 | 236 | ≥5 years | 0.95 g/l | ROC analysis | No surgery | Mixed | OS, PFS | 7 | | Wang XP | 2016 | ESCC | China | 2007–2009 | 210 | ≥5 years | 1.21 g/l | ROC analysis | With surgery | Mixed | OS | 6 | | Guo S | 2016 | RCC | China | 2000–2012 | 755 | ≥5 years | 1.04 g/l | ROC analysis | With surgery | Mixed | OS, DFS | 7 | | Luo XL | 2015 | NPC | China | 2004–2007 | 1196 | ≥5 years | 1.025 g/l | ROC analysis | No surgery | No metastasis | DSS, LRFS, DMFS | 8 | | Jiang R | 2014 | NPC | China | 2003–2009 | 807 | ≥5 years | 1.065 g/l | ROC analysis | No surgery | Metastasis | OS | 7 |
|
|
NSCLC: non-small cell lung cancer; GC: gastric cancer; NPC: nasopharyngeal carcinoma; BC: breast cancer; CRC: colorectal cancer; HCC: hepatocellular carcinoma; ENKTL: extranodal natural killer (NK)/T-cell lymphoma, nasal type; ESCC: esophageal squamous cell carcinoma; RCC: renal cell cancer; OS: overall survival; CSS: cancer-specific survival; TTR: time to recurrence; DFS: disease-free survival; PFS: progression-free survival; DSS: disease-specific survival; DMFS: distant metastasis-free survival; LRFS: locoregional recurrence-free survival; ROC: the receiver operating characteristic curve.
|
